SCOP Search:   
        by sunid, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: All alpha proteins (14657)
(-)
Fold: Cyclin-like (137)
(-)
Superfamily: Cyclin-like (137)
(-)
Family: Cyclin (117)
(-)
Protein domain: Cyclin A (82)
(-)
Cow (Bos taurus) [TaxId: 9913] (9)
1VINA:181-308; A:309-432BOVINE CYCLIN A3
2G9XB:171-309; B:310-432; D:171-309; D:310-432STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
3BHTB:171-308; B:309-432; D:171-308; D:309-432STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
3BHUB:171-308; B:309-432; D:171-308; D:309-432STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
3BHVB:171-308; B:309-432; D:171-308; D:309-432STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
3DDPB:171-309; B:310-432; D:171-309; D:310-438STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
3DDQB:171-309; B:310-432; D:171-309; D:310-439STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
3DOGB:171-309; B:310-432; D:171-309; D:310-434STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
3MY5B:171-308; D:171-308; D:309-432; B:309-432CDK2/CYCLINA IN COMPLEX WITH DRB
(-)
Human (Homo sapiens) [TaxId: 9606] (73)
1E9HB:175-309; B:310-432; D:175-309; D:310-432THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
1FINB:173-309; B:310-432; D:173-309; D:310-432CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
1FVVB:173-309; B:310-432; D:173-309; D:310-432THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
1GY3B:175-309; B:310-432; D:175-309; D:310-432PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE
1H1PB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1H1QB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
1H1RB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
1H1SB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
1H24B:175-309; B:310-432; D:175-309; D:310-432CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
1H25B:175-309; B:310-432; D:175-309; D:310-432CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1H26B:175-309; D:175-309; D:310-432; B:310-432CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
1H27B:175-309; B:310-432; D:175-309; D:310-432CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
1H28B:175-309; B:310-432; D:175-309; D:310-432CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
1JSTB:175-309; B:310-432; D:175-309; D:310-432PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
1JSUB:175-309; B:310-432P27(KIP1)/CYCLIN A/CDK2 COMPLEX
1OGUB:178-309; B:310-432; D:178-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1OI9B:175-309; B:310-432; D:178-309; D:310-430STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIUB:177-309; B:310-432; D:177-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIYB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OKVB:175-309; B:310-432; D:173-309; D:310-432CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
1OKWB:175-309; B:310-432; D:175-309; D:310-432CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
1OL1B:175-309; B:310-432; D:175-309; D:310-432CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
1OL2B:175-309; B:310-432; D:175-309; D:310-432CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
1P5EB:175-309; B:310-432; D:175-309; D:310-432THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS)
1PKDB:175-309; B:310-432; D:175-309; D:310-432THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A
1QMZB:175-309; B:310-432; D:175-309; D:310-432PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1URCB:175-309; B:310-432; D:175-309; D:310-432CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
1VYWB:175-309; B:310-432; D:178-309; D:310-432STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2BKZB:176-309; B:310-432; D:178-309; D:310-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2BPMB:175-309; B:310-432; D:178-309; D:310-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2C4GB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2C5NB:175-309; B:310-432; D:175-309; D:310-432DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5OB:175-309; B:310-432; D:175-309; D:310-432DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5VB:175-309; B:310-432; D:175-309; D:310-432DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5XB:175-309; B:310-432; D:175-309; D:310-432DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C6TB:175-309; B:310-432; D:175-309; D:310-432CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2CCHB:181-308; B:309-432; D:181-308; D:309-431THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE
2CCIB:181-308; B:309-432; D:181-308; D:309-432CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2CJMB:176-309; B:310-432; D:176-309; D:310-432MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
2I40B:175-309; B:310-431; D:178-309; D:310-432CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2IW6B:176-309; B:310-432; D:178-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2IW8B:176-309; B:310-432; D:178-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2IW9B:176-309; B:310-432; D:178-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2UUEB:175-309; B:310-432; D:175-309; D:310-432REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2UZBB:175-309; B:310-432; D:175-309; D:310-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZDB:175-309; B:310-432; D:175-309; D:310-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZEB:175-309; B:310-432; D:175-309; D:310-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZLB:176-309; B:310-432; D:176-309; D:310-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2V22B:175-309; B:310-432; D:175-309; D:310-432REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2WEVB:175-309; B:310-432; D:175-309; D:310-432TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WFYB:176-309; B:310-432; D:173-309; D:310-432TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WHBB:175-309; B:310-432; D:175-309; D:310-432TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WIHB:176-309; B:310-432; D:176-309; D:310-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2WIPB:175-309; B:310-432; D:178-309; D:310-432STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID
2WPAB:175-309; B:310-432; D:179-309; D:310-432OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4-C PYRAZOLES: IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2WXVB:176-309; B:310-432; D:176-309; D:310-432STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(4,3-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
3EIDB:176-309; B:310-432; D:178-309; D:310-432CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3EJ1B:181-308; B:309-432; D:181-308; D:309-432CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3F5XB:177-309; B:310-432; D:178-309; D:310-432CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
4CFNB:177-309; B:310-432; D:176-309; D:310-432STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4CFWB:175-309; B:310-432; D:176-309; D:310-432STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4EOIB:175-309; B:310-432; D:178-309; D:310-432THR 160 PHOSPHORYLATED CDK2 K89D, Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOJB:176-309; B:310-432; D:176-309; D:310-431THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EOKB:175-309; B:310-432; D:176-309; D:310-431THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
4EOLB:176-309; B:310-432; D:176-309; D:310-431THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOMB:176-309; B:310-432; D:176-309; D:310-429THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EONB:176-309; B:310-432; D:175-309; D:310-431THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOOB:175-309; B:310-432; D:176-309; D:310-429THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EOPB:176-309; D:175-309; D:310-429; B:310-432THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOQB:176-309; B:310-432; D:176-309; D:310-429THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EORB:176-309; B:310-432; D:175-309; D:310-429THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
4EOSB:176-309; B:310-432; D:175-309; D:310-429THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4FX3B:176-309; B:310-432; D:175-309; D:310-432CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR